Sean Proehl - Dermata Therapeutics Senior Development
| DRMAW Stock | USD 0.01 0.00 0.00% |
Executive
Sean Proehl is Senior Development of Dermata Therapeutics Warrant
| Address | 3525 Del Mar Heights Road, San Diego, CA, United States, 92130 |
| Phone | 858 800 2543 |
| Web | https://www.dermatarx.com |
Dermata Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.9068) % which means that it has lost $0.9068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.7301) %, meaning that it generated substantial loss on money invested by shareholders. Dermata Therapeutics' management efficiency ratios could be used to measure how well Dermata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.03 in 2024. Return On Capital Employed is likely to drop to -1.33 in 2024. Debt To Assets is likely to climb to 5.53 in 2024, whereas Total Assets are likely to drop slightly above 6.4 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD MBA | Eliem Therapeutics | 50 | |
| MD FAAP | Lumos Pharma | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Alpa Parikh | Lumos Pharma | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Lisa MD | Seres Therapeutics | 65 | |
| Eddie MBA | Lumos Pharma | N/A | |
Management Performance
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.91 |
Dermata Therapeutics Leadership Team
Elected by the shareholders, the Dermata Therapeutics' board of directors comprises two types of representatives: Dermata Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dermata. The board's role is to monitor Dermata Therapeutics' management team and ensure that shareholders' interests are well served. Dermata Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dermata Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mr MPH, VP Devel | ||
| Maria MBA, Senior Assurance | ||
| Gerald Proehl, Chairman, CoFounder | ||
| Kyri Hoose, VP CFO | ||
| Sean Proehl, Senior Development | ||
| David Hale, CoFounder Director | ||
| Dr MPH, Senior Officer |
Dermata Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dermata Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.91 | ||||
| Number Of Shares Shorted | 1.2 K | ||||
| EBITDA | 247.22 K | ||||
| Net Income | (7.79 M) | ||||
| Total Debt | 1.62 M | ||||
| Book Value Per Share | 24.25 X | ||||
| Cash Flow From Operations | (6.41 M) | ||||
| Earnings Per Share | (2.16) X | ||||
| Beta | 0.79 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.